YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-23
DOI
10.1038/s41416-020-0952-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials
- (2019) Lei Wang et al. CANCER SCIENCE
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- YES1 is a targetable oncogene in cancers harboring YES1 gene amplification
- (2019) Natsuki Hamanaka et al. CANCER RESEARCH
- HER2-positive breast cancer: Current and new therapeutic strategies
- (2018) Santiago Escrivá-de-Romaní et al. BREAST
- Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
- (2018) Deborah B Doroshow et al. Future Oncology
- Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer
- (2018) Özge Saatci et al. ONCOGENE
- YES1amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
- (2018) Pang-Dian Fan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
- (2018) Lei Wang et al. CANCER SCIENCE
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1
- (2017) Zheng Fang et al. Molecular Cancer
- Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kδ/Akt and NFκB induction in a murine asthma model
- (2017) Ahmed Z. El-Hashim et al. Scientific Reports
- TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- (2016) María F. Mercogliano et al. CLINICAL CANCER RESEARCH
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
- (2014) I. E. Krop et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer
- (2013) Manfred Welslau et al. CANCER
- RON confers lapatinib resistance in HER2-positive breast cancer cells
- (2013) Quanren Wang et al. CANCER LETTERS
- (5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition
- (2012) Lei Wang et al. CANCER LETTERS
- β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
- (2012) Joseph Rosenbluh et al. CELL
- Src family kinases and paclitaxel sensitivity
- (2011) Xiao-Feng Le et al. CANCER BIOLOGY & THERAPY
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
- (2011) J. C. Montero et al. CLINICAL CANCER RESEARCH
- Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
- (2011) Manish R. Sharma et al. INVESTIGATIONAL NEW DRUGS
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
- (2010) Deric L. Wheeler et al. CANCER BIOLOGY & THERAPY
- Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
- (2010) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy
- (2010) Roshawn G. Watson et al. EUROPEAN JOURNAL OF CANCER
- A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)
- (2010) Antonius A. Miller et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
- (2008) Oliver Hantschel et al. LEUKEMIA & LYMPHOMA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now